Megestrol Continued Despite Pharmacist Recommendation to Discontinue
Summary
Medical supervision was not ensured for one resident reviewed for drug regimen review. The resident had diagnoses including schizoaffective disorder, type 2 diabetes mellitus, and morbid obesity, with a documented weight of 413 to 415 pounds and intact cognition. The consultant pharmacist’s medication regimen review identified long-term use of Megestrol beyond 30 days and recommended discontinuation or clarification of the indication if the medication continued. The response to the review documented to discontinue Megace and noted no GLP-1 medication until the resident was monitored off Megace. Despite the recommendation and the physician’s agreement to discontinue the medication, the resident continued to receive Megestrol. The record showed a physician renewal order for Megestrol 400 mg/10 ml once daily, and the MAR documented repeated administration of the medication in December 2025, January 2026, and February 2026. During interviews, the Medical Director stated the pharmacist’s recommendation to discontinue Megestrol had been reviewed and agreed with, and that an order was given to discontinue it, but the Nurse Practitioner reordered the medication. The DON was unable to produce the discontinuation order, and the consultant pharmacist stated the recommendation had not been addressed during the following month.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release June 24, 2026) and official state health department websites — never guesswork.
Trusted by long-term care providers and associations.



